Sign up
Pharma Capital

VolitionRx signs MoU with National Taiwan University for two large clinical studies

Cameron Reynolds, president and chief executive of VolitionRx Ltd (NYSEAMERICAN:VNRX) caught up with Proactive to chat through the group's Q3 update as well as the news they've signed a memorandum of understanding with the National Taiwan University to conduct two large clinical studies.

The studies will entail taking some 7,000 patient samples.

he first trial would be a large scale multi-country, multi-center and multi-ethnic study in the Asia Pacific region, including 5,000 asymptomatic colorectal cancer screening subjects.

The second trial will include up to 2,000 symptomatic colorectal cancer patients.

 

View full VNRX profile

VolitionRx Timeline

View All

© biotech Capital 2017

Biotech Capital, a subsidiary of Proactive Investors, acts as the vanguard for listed biotech companies to interact with institutional and highly capitalised investors.
Headquartered in London, Biotech Capital is led by a team of Europe's leading analysts and journalists, publishing daily content, covering all key movements in the Biotechnology market.